Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors

血管生成抑制剂双重治疗的体内微创疗效评价

• 批准号: 23591763
• 负责人: SHINICHI Ota
• 金额: $ 3.41万
• 依托单位: Shiga University of Medical Science
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591763/
• 关键词: 血管新生阻害薬; 抗腫瘍効果; 画像評価; 病理評価

The anti-tumor effect of the angiogenesis inhibitors increased in the following order; bevacizumab, sorafenib, and thalidomide. The anti-tumor effects of the dual therapies except sorafenib and thalidomide were lower than those of the single therapies. However, the numbers of the dual therapies were not enough to consider them, therefore, more studies about the dual therapies were necessary. When the anti-tumor effect of the angiogenesis inhibitor was determined, the best and simple way was to measure the change of the tumor sizes before and after the therapy using CT. To measure the change of enhancement ratio using CT / DSA and to evaluate the necrosis ratio and the numbers of tumor vessels pathologically were unfitted for the response evaluation of the angiogenesis inhibitors.

血管生成抑制剂的抗肿瘤作用按以下顺序增加：贝伐单抗、索拉非尼和沙利度胺。除索拉非尼和沙利度胺外，其他联合治疗的抗肿瘤效果均低于单药治疗。但目前双药治疗的数量还不足以考虑双药治疗，因此需要对双药治疗进行更多的研究。在确定血管生成抑制剂的抗肿瘤作用时，最好和最简单的方法是使用CT测量治疗前后肿瘤大小的变化。用CT / DSA测量增强率的变化，用病理学方法评价肿瘤坏死率和肿瘤血管数，不适合评价血管生成抑制剂的疗效。